Threshold halting enrollment in clinical trial

Redwood City biopharmaceutical firm Threshold Pharmaceuticals Inc. (THLD) will stop enrollment in a Phase 2 clinical trial evaluating the use of glufosfamide in patients with recurrent, sensitive small cell lung cancer.

The first stage of the trial, which included 21 patients, showed only one confirmed partial response. Under the design of the trial, three or more responses were required before an additional 29 patients would have been enrolled.

Patients already enrolled will be given the option to continue in the trial.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

SFUSD: City schools to stay closed for the rest of the year

District joins five other Bay Area districts in announcing closure

Coronavirus cases exceed 600 in SF; 9 reported dead

Mayor launches data tracker after calls for transparency

Breed changes plans for massive new Moscone West homeless shelter

City now moving more shelter residents to hotel rooms after three test positive for COVID-19

Two test positive at SF homeless shelter in South of Market

Two people staying at a homeless shelter in San Francisco’s South of… Continue reading

Testing and re-testing continues at Laguna Honda as total cases increase to 16

Last week, the total number of diagnosed coronavirus cases at Laguna Honda,… Continue reading

Most Read